Dimitrios Spentzos

Harvard University — United States

Medicine · Health Sciences

29h-index3.6kcitations92works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(24), Cancer-related molecular mechanisms research(18), Genomics, phytochemicals, and oxidative stress(17), Bone Tumor Diagnosis and Treatments(16), MicroRNA in disease regulation(14)

Publications92 total

Adjuvant chemotherapy in localized, resectable extremity and truncal soft tissue sarcoma and survival outcomes – A systematic review and meta‐analysis of randomized controlled trials
Cancer·2025· 5 citedOpen Access
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics
2024· 1 citedOpen Access
Data from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Supplementary Figure legends from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Table S2 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Table S3 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Data from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Table S1 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Table S1 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Figure S1-2 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Figure S1-2 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Supplementary Figure legends from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Table S2 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Table S3 from Expression and Therapeutic Potential of SOX9 in Chordoma
2023Open Access
Supplemental Table 1 from Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
2023Open Access
Supplemental Figure 1 from Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
2023Open Access
Supplemental Figure 2 from Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
2023Open Access
Supplemental Table 2 from Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
2023Open Access
Supplemental Table 1 from Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
2023Open Access
Supplemental Table 3 from Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Towia A. Libermann(15), Edwin Choy(12), Panagiotis A. Konstantinopoulos(10), Hasan H. Otu(10), Andrew D. Kelly(10), Benjamin Haibe‐Kains(9), John Quackenbush(9), Gregory M. Coté(9), Stephen A. Cannistra(8), Franck Grall(8), Elena Fountzilas(7), Cassandra C. Garbutt(7), Santiago A. Lozano‐Calderón(7), Jeffrey D. Goldsmith(6), Manuel Aivado(6), Francis J. Hornicek(6), Christopher B. Lietz(6), Nancy Francoeur(5), G. Petur Nielsen(5), Vikram Deshpande(5)